Gravity Diagnostics Partners with Kroger Health to Expand COVID-19 Testing with Home Collection Kits – News- Graphic

COVINGTON, Ky., July 1, 2020 /PRNewswire/ --Gravity Diagnostics, a CLIA laboratory headquartered in Covington, Kentucky, today announced the U.S. Food and Drug Administration (FDA) has granted an update to their Emergency Use Authorization (EUA) to include use of nasal swab specimens that are self-collected by individuals using the Kroger Health COVID-19 Test Home Collection Kit. This was an addition to their earlier EUA that was granted on June 1st, 2020. The testing solution combines the safety and convenience of at-home specimen collection with the expert guidance of a Kroger Health clinician through video telehealth visit.

On March 16th, Gravity Diagnostics began processing COVID-19 samples with a vision to bring increased testing to their local communities, partnering with the Commonwealth of Kentucky to serve the healthcare facilities across the state and later with Kroger Health to bring more testing to Kentucky and nationwide via drive through testing sites. This next big step with Kroger Health will allow the two organizations to make a more widespread impact for COVID-19 testing across the nation, through an innovative method focused on quality, compliance, and patient experience.

Kroger Health will make the kits available to frontline associates across Kroger's Family of Companies based on medical need first, and will expand rapidly from there, with a goal of processing up to 60,000 per week by the end of July. Gravity Diagnostics to date has processed over 250,000 COVID-19 samples. The relatively small laboratory is evolving quickly to meet the need and scale through hiring of personnel and expansion of equipment and new laboratory space.

"Everything we have done during this time is with the people of our communities and nation in mind. After partnering with Kroger Health to execute their nationwide drive throughs, we were enthusiastic to continue to expand testing through our partnership in a way that is flexible and accessible during this critical time of working to reopen the United States," said Tony Remington, CEO of Gravity Diagnostics. "We are humbled to be a part of just one of the ways Kroger Health is executing a larger vision of how the healthcare industry is evolving."

About Gravity DiagnosticsGravity Diagnostics is a full-service state-of-the-art CLIA laboratory licensed in all 50 states providing innovative laboratory testing including Infectious Disease (Upper Respiratory and Sexually Transmitted), Toxicology, and Pharmacogenomics. We are an advocate for physicians, patients, and our communities, supporting them with unsurpassed integrity, regulatory compliance, and clinical expertise. Learn more by visiting gravitydiagnostics.com.

About Kroger Health:Kroger Health, the healthcare division of The Kroger Co., is one of America's leading retail healthcare organizations, with over 2,000 pharmacies and 200 clinics in 35 states serving more than 14 million customers. Their team of 22,000 healthcare practitioners - from pharmacists and nurse practitioners, to dietitians and technicians are committed to helping people live healthier lives. They believe in practicing at the top of our licenses and enabling "food as medicine" to help prevent or manage certain diseases. Learn more atwww.krogerhealth.com.

About The Kroger Co.:At The Kroger Co. (NYSE: KR), we are Fresh for Everyone and dedicated to their Purpose: ToFeed the Human Spirit. They are, across our family of companies, nearly half a million associates who serve over 11 million customers daily through a seamless shopping experience under a variety ofbanner names. They are committed to creating #ZeroHungerZeroWaste communities by 2025. To learn more about them, visit theirnewsroomand investor relationssite.

Contact: media@gravitydiagnostics.com

Original post:
Gravity Diagnostics Partners with Kroger Health to Expand COVID-19 Testing with Home Collection Kits - News- Graphic

Precision Medicine Market 2020: Industry Analysis and Detailed Profiles of Top Industry Players are Neon Therapeutics, Moderna, Inc, Merck & Co.,…

Global Precision Medicine market report provides an in-depth overview of Product Specification, technology, product type and production analysis considering major factors such as Revenue, Cost, Gross and Gross Margin. The company profiles of all the key players and brands that are dominating the Precision Medicine market with moves like product launches, joint ventures, merges and accusations which in turn is affecting the sales, import, export, revenue and CAGR values are mentioned in the report. The report is generated based on the market type, size of the organization, availability on-premises and the end-users organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa.

Global Precision Medicine Marketto grow with a substantial CAGR in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and accelerating demand of novel therapies to prevent of cancer related disorders are the key factors for lucrative growth of market

Key Market Players:

Few of the major competitors currently working in the global precision medicine market are Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC., F. Hoffmann-La Roche Ltd, CureVac AG, CELLDEX THERAPEUTICS, BIONTECH SE, Advaxis, Inc, GlaxoSmithKline plc, Bioven International Sdn Bhd, Agenus Inc., Immatics Biotechnologies GmbH, Immunovative Therapies, Bristol-Myers Squibb Company, Gritstone Oncology, NantKwest, Inc among others.

Download Free PDF Sample Copy of[emailprotected]http://databridgemarketresearch.com/request-a-sample/?dbmr=global-precision-medicine-market

Global Precision Medicine MarketBy Application (Diagnostics, Therapeutics and Others), Technologies (Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics and Others), Indication (Oncology, Central Nervous System (CNS) Disorders, Immunology Disorders, Respiratory Disorders, Others), Drugs (Alectinib, Osimertinib, Mepolizumab,Aripiprazole lauroxil and Others), Route of Administration (Oral,Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Competitive Analysis:

The precision medicine market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of mass spectrometry market for global, Europe, North America, Asia Pacific and South America.

Market Drivers

Market Restraints

Talk to The Author of Report @http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-precision-medicine-market

Market Definition:

Precision medicines is also known as personalized medicines is an innovative approach to the patient care for disease treatment, diagnosis and prevention base on the persons individual genes. It allows doctors or physicians to select treatment option based on the patients genetic understanding of their disease.

According to the data published in PerMedCoalition, it was estimated that the USFDA has approved 25 novels personalized medicines in the year of 2018. These growing approvals annually by the regulatory authorities and rise in oncology and CNS disorders worldwide are the key factors for market growth.

Grab Your Report at an Impressive 30% Discount! Please click[emailprotected]https://www.databridgemarketresearch.com/request-a-discount/global-precision-medicine-market

Key Developments in the Market:

Competitive Analysis:

Global precision medicine market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global precision medicine market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Segmentation:

By technology:-big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others.

By application:- oncology, hematology, infectious diseases, cardiology, neurology, endocrinology, pulmonary diseases, ophthalmology, metabolic diseases, pharmagenomics, and others.

On the basis of end-users:- pharmaceuticals, biotechnology, diagnostic companies, laboratories, and healthcare it specialist.

On the basis of geography:- North America & South America, Europe, Asia-Pacific, and Middle East & Africa. U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others.

In 2017, North America is expected to dominate the market.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Originally posted here:
Precision Medicine Market 2020: Industry Analysis and Detailed Profiles of Top Industry Players are Neon Therapeutics, Moderna, Inc, Merck & Co.,...

Solving problems by working together: Could quantum computing hold the key to Covid-19? – ITProPortal

Given the enormous potential for quantum computing to change the way we forecast, model and understand the world, many are beginning to question whether it could have helped to better prepare us all for a global pandemic such as the Covid-19 crisis. Governments, organisations and the public are continuing the quest for answers about when this crisis will end and how we can find a way out of the current state of lockdown, and we are all continuing to learn through incremental and experimental steps. It certainly seems plausible that the high compute simulation capabilities of our most revolutionary technology could hold some of the answers and enable us to respond in a more coherent and impactful way.

Big investments have already been made in quantum computing, as countries and companies battle to create the first quantum supercomputer, so they can harness the power of this awesome technology. The World Economic Forum has also recognised the important role that this technology will play in our future, and has a dedicated Global Future Council to drive collaboration between public and private sector organisations engaged in the development of Quantum Computing. Although its unlikely to result in any overnight miracles, its understandable that many are thinking about whether these huge efforts and investments can be turned towards the mutual challenge we face in finding a solution to the Covid-19 pandemic.

There are already some ground-breaking use-cases for quantum computing within the healthcare industry. Where in the past some scientific breakthroughs such as the discovery of penicillin came completely by accident, quantum computing puts scientists in a much stronger position to find what they were looking for, faster. Quantum raises capacity to such a high degree that it would be possible to model penicillin using just a third of the processing power a classical computer would require to do the job meaning it can do more with less, at greater speed.

In the battle against Covid-19, the US Department of Energys Oak Ridge National Laboratory (ORNL) is already using quantum supercomputers in its search for drug compounds that can treat the disease. IBM has also been using quantum supercomputers to run simulations on thousands of compounds to try and identify which of them is most likely to attach to the spike that Covid-19 uses to inject genetic material into healthy cells, and thereby prevent it. It has already emerged with 77 promising drugs that are worth further investigation and development progress that would have taken years if traditional computing power had been used.

Other businesses are likely to be keen to follow in the footsteps of these examples, and play their own part in dealing with the crisis, but to date its only been the worlds largest organisations that have been using quantum power. At present, many businesses simply dont have the skills and resources needed to fabricate, verify, architect and launch a large-scale quantum computer on their own.

It will be easier to overcome these barriers, and enable more organisations to start getting to work with quantum computing, if they open themselves up to collaboration with partners, rather than trying to go it alone. Instead of locking away their secrets, businesses must be willing to work within an open ecosystem; finding mutually beneficial partnerships will make it much more realistic to drive things forward.

The tech giants have made a lot of early progress with quantum, and partnering with them could prove extremely valuable. Google, for example, claims to have developed a machine that can solve a problem in 200 seconds that would take the worlds fastest supercomputer 10,000 years imagine adding that kind of firepower to your computing arsenal. Google, IBM and Microsoft have already got the ball rolling by creating their own quantum partner networks. IBM Q and Microsoft Quantum Network bring together start-ups, universities, research labs, and Fortune 500 companies, enabling them to enjoy the benefits of exploring and learning together. The Google AI quantum initiative brings together strong academia support along with start-up collaboration on open source frameworks and tools in their lab. Collaborating in this manner, businesses can potentially play their own part in solving the Covid-19 crisis, or preventing future pandemics from doing as much damage.

Those that are leading the way in quantum computing are taking a collaborative approach, acknowledging that no one organisation holds all the answers or all the best ideas. This approach will prove particularly beneficial as we search for a solution to the Covid-19 crisis: its in everyones interests to find an exit to the global shutdown and build knowledge that means we are better-prepared for future outbreaks.

Looking at the bigger picture, despite all the progress that is being made with quantum, traditional computing will still have an important role to play in the short to medium term. Strategically, it makes sense to have quantum as the exploratory left side of the brain, while traditional systems remain in place for key business-as-usual functions. If they can think about quantum-related work in this manner, businesses should begin to feel more comfortable making discoveries and breakthroughs together. This will allow them to speed up the time to market so that ideas can be explored, and new ground broken, much faster than ever before and thats exactly what the world needs right now.

Kalyan Kumar, CVP & CTO, IT Services, HCL Technologies

Go here to read the rest:
Solving problems by working together: Could quantum computing hold the key to Covid-19? - ITProPortal

Menten AIs combination of buzzword bingo brings AI and quantum computing to drug discovery – TechCrunch

Menten AI has an impressive founding team and a pitch that combines some of the hottest trends in tech to pursue one of the biggest problems in healthcare new drug discovery. The company is also $4 million richer with a seed investment from firms including Uncork Capital and Khosla Ventures to build out its business.

Menten AIs pitch to investors was the combination of quantum computing and machine learning to discover new drugs that sit between small molecules and large biologics, according to the companys co-founder Hans Melo.

A graduate of the Y Combinator accelerator, which also participated in the round alongside Social Impact Capital*, Menten AI looks to design proteins from scratch. Its a heavier lift than some might expect, because, as Melo said in an interview, it takes a lot of work to make an actual drug.

Menten AI is working with peptides, which are strings of amino acid chains similar to proteins that have the potential to slow aging, reduce inflammation and get rid of pathogens in the body.

As a drug modality [peptides] are quite new, says Melo. Until recently it was really hard to design them computationally and people tried to focus on genetically modifying them.

Peptides have the benefit of getting through membranes and into cells where they can combine with targets that are too large for small molecules, according to Melo.

Most drug targets are not addressable with either small molecules or biologics, according to Melo, which means theres a huge untapped potential market for peptide therapies.

Menten AI is already working on a COVID-19 therapeutic, although the companys young chief executive declined to disclose too many details about it. Another area of interest is in neurological disorders, where the founding team members have some expertise.

Image of peptide molecules. Image Courtesy: D-Wave

While Menten AIs targets are interesting, the approach that the company is taking, using quantum computing to potentially drive down the cost and accelerate the time to market, is equally compelling for investors.

Its also unproven. Right now, there isnt a quantum advantage to using the novel computing technology versus traditional computing. Something that Melo freely admits.

Were not claiming a quantum advantage, but were not claiming a quantum disadvantage, is the way the young entrepreneur puts it. We have come up with a different way of solving the problem that may scale better. We havent proven an advantage.

Still, the company is an early indicator of the kinds of services quantum computing could offer, and its with that in mind that Menten AI partnered with some of the leading independent quantum computing companies, D-Wave and Rigetti Computing, to work on applications of their technology.

The emphasis on quantum computing also differentiates it from larger publicly traded competitors like Schrdinger and Codexis.

So does the pedigree of its founding team, according to Uncork Capital investor, Jeff Clavier. Its really the unique team that they formed, Clavier said of his decision to invest in the early-stage company. Theres Hans the CEO who is more on the quantum side; theres Tamas [Gorbe] on the bio side and theres Vikram [Mulligan] who developed the research. Its kind of a unique fantastic team that came together to work on the opportunity.

Clavier has also acknowledged the possibility that it might not work.

Can they really produce anything interesting at the end? he asked. Its still an early-stage company and we may fall flat on our face or they may come up with really new ways to make new peptides.

Its probably not a bad idea to take a bet on Melo, who worked with Mulligan, a researcher from the Flatiron Institute focused on computational biology, to produce some of the early research into the creation of new peptides using D-Waves quantum computing.

Novel peptide structures created using D-Waves quantum computers. Image Courtesy: D-Wave

While Melo and Mulligan were the initial researchers working on the technology that would become Menten AI, Gorbe was added to the founding team to get the company some exposure into the world of chemistry and enzymatic applications for its new virtual protein manufacturing technology.

The gamble paid off in the form of pilot projects (also undisclosed) that focus on the development of enzymes for agricultural applications and pharmaceuticals.

At the end of the day what theyre doing is theyre using advanced computing to figure out what is the optimal placement of those clinical compounds in a way that is less based on those sensitive tests and more bound on those theories, said Clavier.

*This post was updated to add that Social Impact Capital invested in the round. Khosla, Social Impact, and Uncork each invested $1 million into Menten AI.

Visit link:
Menten AIs combination of buzzword bingo brings AI and quantum computing to drug discovery - TechCrunch

Better encryption for wireless privacy at the dawn of quantum computing – UC Riverside

For the widest possible and mobile Internet coverage, wireless communications are essential. But due to the open nature of wireless transmissions, information security is a unique issue of challenge. The widely deployed methods for information security are based on digital encryption, which in turn requires two or more legitimate parties to share a secret key.

The distribution of a secrecy key via zero-distance physical contact is inconvenient in general and impossible in situations where too little time is available. The conventional solution to this challenge is to use the public-key infrastructure, or PKI, for secret key distribution. Yet, PKI is based on computational hardness of factoring, for example, which is known to be increasingly threatened by quantum computing. Some predictions suggest that such a threat could become a reality within 15 years.

In order to provide Internet coverage for every possible spot on the planet, such as remote islands and mountains, a low-orbiting satellite communication network is rapidly being developed. A satellite can transmit or receive streams of digital information to or from terrestrial stations. But the geographical exposure of these streams is large and easily prone to eavesdropping. For applications such as satellite communications, how can we guarantee information security even if quantum computers become readily available in the near future?

Yingbo Huas Lab of Signals, Systems and Networks in the Department of Electrical and Computer Engineering, which has been supported in part by Army, has aimed to develop reliable and secure transmission, or RESET, schemes for future wireless networks. RESET guarantees that the secret information is not only received reliably by legitimate receiver but also secure from eavesdropper with any channel superiority.

In particular, Huas Lab has developed a physical layer encryption method that could be immune to the threat of quantum computing. They are actively engaged in further research of this and other related methods.

For the physical layer encryption proposed by Huas lab, only partial information is extracted from randomized matrices such as the principal singular vector of each matrix modulated by secret physical feature approximately shared by legitimate parties. The principal singular vector of a matrix is not a reversible function of the matrix. This seems to suggest that a quantum computer is unable to perform a task that is rather easy on a classical computer. If this is true, then the physical layer encryption should be immune from attacks via quantum computing. Unlike the number theory based encryption methods which are vulnerable to quantum attacks, Huas physical layer encryption is based on continuous encryption functions that are still yet to be developed.

Read the original here:
Better encryption for wireless privacy at the dawn of quantum computing - UC Riverside

Quantum Computing gains as it kicks off commercialization phase with its Mukai quantum computing software – Proactive Investors USA & Canada

Set up at the beginning of 2018, Quantum bills itself as the first publicly traded pure-play quantum computing company

QuantumComputing Inc (), an advanced technology company developing quantum-ready applications and tools,said Wednesday that it is set to gain as it has entered the key commercialization phase as the only public pure-play in the quantum computing space.

The Leesburg, Virginia-based company has kicked off the official commercial launch of its Mukai quantum computing software execution platform. Last week, the company introduced a new trial access program that demonstrates Mukais power to solve real-world problems.

Quantums stock recently traded 1.3%higher to $3.91 a share inNew York.

READ:Quantum Computing launches free trial of Mukai quantum computing application platform

According to the company, the trial will enable developers to discover how they can migrate their existing applications to quantum-ready solutions and realize superior performance even when running their solutions on classical Intel or AMD processor-based computers.

The trial is designed to encourage and facilitate quantum application development to solve real world problems at breakthrough speed and not tomorrow, but today, the company said in a statement.

There are only a handful of quantum software experts in the world, and fortunately for us, this includes Mike and Steve," commented Quantum CEO Robert Liscouski. They have been doing an outstanding job building out our software engineering teams, developing our first quantum-ready products, and preparing QCI for commercial success.

Quantum kicked off 2020 with the public release of its first quantum-ready software product, the QCI Quantum Asset Allocator (QAA). This solution is designed to help portfolio managers maximize returns by calculating their optimal asset allocations, said the company.

QAA is the first of a series of Quantum products that will leverage quantum techniques to provide differentiated performance on both classical computers and on a variety of early-stage quantum computers, added the company. Naturally, Quantum is looking to convert its QAA beta users into long-term customers.

The core of our strategy has been to anticipate the direction of the market and be ahead of it by offering unique solutions that establish QCI as a market leader, said Liscouski. We will be driven by the market, but in turn will drive the market by helping our customers realize their quantum-enabled future.

The company said that while quantum computing is typically a high-dollar investment given the "sophisticated and costly hardware," Mukai makes quantum application development affordable and scalable compared to running solutions on intermediate quantum computers, like those offered by D-Wave, Fujitsu, IBM and Rigetti.

Mukai addresses the quantum computing market which is tipped to grow at a 23.2% compound annual growth rate to $9.1 billion by 2030, according to Tractica.

Contact the author Uttara Choudhury at [emailprotected]

Follow her on Twitter: @UttaraProactive

Link:
Quantum Computing gains as it kicks off commercialization phase with its Mukai quantum computing software - Proactive Investors USA & Canada

Is quantum computing ready to leap into the real world? – ARNnet

Market research firm IDC predicts that by 2023, 25% of Fortune 500 companies will gain a competitive advantage from quantum computing.

Its a bold prediction given the current dearth of real-world examples of quantum computing in action. However, theres plenty of industry activity to back up IDCs forecast. In fact, early this year at the Consumer Electronics Show the biggest buzz wasnt the newest smartphone, wearable device or autonomous-driving technology, but rather unprecedented computing power based on an area of quantum physics Albert Einstein described as "spooky action at a distance."

While quantum computing hasnt yet factored into solving worldwide problems such as the coronavirus pandemic, that is exactly the type of problem quantum has the potential to address. That potential will turn into a reality, according IBM, one of a handful of tech giants leading the quantum charge. This is the decade that quantum computing gets real, says Katie Pizzolato, director at IBM QStart.

For that reason, Pizzolato said, it was important to keep quantum public-facing rather than keep it a technology buried in research facilities. We wanted to get quantum out of the labs and into the real world, she said in reference to IBMs strong presence at CES.

Companies such as Google, Microsoft, D-Wave and Regetti are also eager to move quantum forward, and based on IDCs recent report Quantum Computing Adoption Trends: 2020 Survey Findings, the technology is building momentum.

According to responses from 520 IT and line-of-business professionals, quantum computing budgets and implementations will increase in the next 18-24 months. Half of all respondents to the IDC survey reported that funds allocated for quantum computing accounted for just 0-2% of the annual IT infrastructure in 2019, but will account for 7-10% in the next 24 months. For companies with more than 10,000 employees, the spending increase is more dramatic more than half of respondents will spend between 9% and 14% on quantum technology over the next two years.

Respondents to the IDC survey were clear where they are focusing their attention: 65% of respondents are using to plan to use cloud-based quantum computing, followed by 45% who use or plan to use quantum algorithms (which includes simulators, optimizations, artificial intelligence, machine learning and deep learning). Quantum networks (44%), hybrid quantum computing (40%) and quantum cryptography (33%) round the top five, according to the IDC survey.

Heather West, IDC senior research analyst, Infrastructure Systems, Platforms and Technology and one of the reports authors, says that quantum computing excels at solving large problems where theres so much data. The initial areas of focus will be AI, business intelligence and overall productivity and efficiency, according to the IDC report.

Very few companies have actually operationalized [quantum computing]. The skillsets are so advanced, and few people really understand quantum, West said, adding that were still at the experimentation stage with algorithms as companies also look to overcome challenges such as cost, security and data transfers between vendors. West points out, however, that there are already practical use cases in areas such as manufacturing and finance.

Right now, West says, the focus is on how to optimize processes. However, in the future, quantum will be applied to larger problems such as how to address climate change and cure diseases.

As IDCs West says, quantum computing isnt without its challenges. IDC cites complex technology, skillset limitations, a lack of available resources, cost, security, data transfer among vendors as barriers to adoption. With so many challenges, its not surprising that when selecting vendors to support quantum technology initiatives big names dominate the responses in the IDC survey. Google tops the list with 37% of respondents citing it as the vendor of choice, followed by Microsoft with 32%, IBM with 27% and Intel with 23&.

What makes quantum computing more powerful than classical computing is that rather relying on binary bits (i.e, either a 1 or 0) quantum computing uses qubits. Qubits can process more data because they can exist in many possible combinations of 1 and 0 simultaneously, known as superposition, processing an enormous number of outcomes.

In addition to superposition, pairs of qubits can be "entangled." This entanglement is what makes quantum computers as powerful as they are. What make it even more intriguing is that no one knows how or why it works, prompting that spooky action description from Einstein.

In classical computing, doubling the amount of bits gives you, as youd expect, twice the computing power. However, thanks to entanglement adding more qubits gives you exponentially more processing power.

If processing power potential is the good news on qubits, their fragile nature is the bad news. Not all qubits are created equal, IBMs Pizzolato says. Qubits are unpredictable and susceptible to environmental noise and errors. After an error they fall back to a binary state of 1 or 0, so the longer the calculation runs without an error, the greater the calculation. The goal is to protect against errors to solve the most challenging problems, Pizzolato says.

How common are these errors? A slight fluctuation in temperature or vibration can cause whats known as "decoherence." And, once a qubit is in decoherence, its calculation has failed and must be run again. For that reason, quantum computers are housed in environments of near absolute zero and with little outside disruption.

More qubits help. The 50 qubits range is when you start to supersede what you can achieve on a supercomputer, says Pizzolato. IBM last fall announced its 14th quantum computer, a 53-qubit system. Its previous quantum computers were 20 qubits. However, quantum is more than qubits. Hardware is at the center of the circle, but then you have the algorithms and the applications, says Pizzolato. More sophisticated algorithms are critical to quantum computings real-world success. Quantum is all about the algorithms you can run and the complexity of those algorithms, she says.

Skills gaps are a challenge for IT in general. With quantum computing, its magnified. Where will the quantum development come from? Peter Rutten, research director and one of the authors of the IDC report, says that the algorithms and application development will come from three distinct personas:

Developers who are intrigued with quantum computing, developers with a physics background (because there are not many jobs in physics) and those working in high-performance-computing operations. Its a seamless transition from HPC algorithms to quantum, Rutten says.

On the one hand, Google, IBM and others appear to be jostling for position in achieving quantum advantage (the point at which quantum computing can solve a program faster than classical computing) and quantum supremacy (when quantum computing solves a program that no conventional computer can solve). In fact, IBM recently publicly refuted Googles claim of achieving quantum supremacy with its 53-qubit computer, its researchers saying that Google failed to fully estimate the resources of a supercomputer, publishing this in an IBM Research blog last October:

Building quantum systems is a feat of science and engineering, and benchmarking them is a formidable challenge," according to an IBM quantum-computing blog. "Googles experiment is an excellent demonstration of the progress in superconducting-based quantum computing, showing state-of-the-art gate fidelities on a 53-qubit device, but it should not be viewed as proof that quantum computers are supreme over classical computers.

On the other hand, despite the top-tier vendors seemingly jockeying for quantum positions, IDGs Rutten said, its not about competitors going head-to-head. Its hard to compare. No one can tell you [whos ahead] because they are measuring progress in different ways, he says. The notion of quantum being a race is silly.

IDCs West concurs, saying that quantum advances will come from the developer community and technology partnerships. Its not so much a race to the end, because there may not be just one answer.

For its part, IBM has a network of 100 partnerships from commercial (e.g, Goldman Sachs, ExxonMobile, Accenture and others), academic (e.g., MIT, Virginia Tech, Johns Hopkins and dozens of others), startups, government and research sectors.

Even with the likes of Google, IBM and Microsoft pushing quantum computing to go from advantage to supremacy, no one knows where the big innovation will come from, Pizzolato says. The MVP is probably a guy in a lab.

Error: Please check your email address.

Read more here:
Is quantum computing ready to leap into the real world? - ARNnet

Quantum Computing Market: In-Depth Market Research and Trends Analysis till 2030 – Cole of Duty

Prophecy Market Insights Quantum Computing market research report provides a comprehensive, 360-degree analysis of the targeted market which helps stakeholders to identify the opportunities as well as challenges during COVID-19 pandemic across the globe.

Quantum Computing Devices Market reports provide in-depth analysis of Top Players, Geography, End users, Applications, Competitor analysis, Revenue, Financial Analysis, Market Share, COVID-19 Analysis, Trends and Forecast 2020-2029. It incorporates market evolution study, involving the current scenario, growth rate, and capacity inflation prospects, based on Porters Five Forces and DROT analyses.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/571

An executive summary provides the markets definition, application, overview, classifications, product specifications, manufacturing processes; raw materials, and cost structures.

Market Dynamics offers drivers, restraints, challenges, trends, and opportunities of the Quantum Computing market

Detailed analysis of the COVID-19 impact will be given in the report, as our analyst and research associates are working hard to understand the impact of COVID-19 disaster on many corporations, sectors and help our clients in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

Segment Level Analysis in terms of types, product, geography, demography, etc. along with market size forecast

Segmentation Overview:

The Quantum Computing research study comprises 100+ market data Tables, Graphs & Figures, Pie Chat to understand detailed analysis of the market. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Quantum Computing market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry.

Request Discount @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/571

Regional and Country- level Analysis different geographical areas are studied deeply and an economical scenario has been offered to support new entrants, leading market players, and investors to regulate emerging economies. The top producers and consumers focus on production, product capacity, value, consumption, growth opportunity, and market share in these key regions, covering

The comprehensive list of Key Market Players along with their market overview, product protocol, key highlights, key financial issues, SWOT analysis, and business strategies. The report dedicatedly offers helpful solutions for players to increase their clients on a global scale and expand their favour significantly over the forecast period. The report also serves strategic decision-making solutions for the clients.

Competitive landscape Analysis provides mergers and acquisitions, collaborations along with new product launches, heat map analysis, and market presence and specificity analysis.

Quantum ComputingMarket Key Players:

Wave Systems Corp, 1QB Information Technologies Inc, QC Ware, Corp, Google Inc, QxBranch LLC, Microsoft Corporation, International Business Machines Corporation, Huawei Technologies Co., Ltd, ID Quantique SA, and Atos SE.

The study analyses the manufacturing and processing requirements, project funding, project cost, project economics, profit margins, predicted returns on investment, etc. With the tables and figures, the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Stakeholders Benefit:

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Read this article:
Quantum Computing Market: In-Depth Market Research and Trends Analysis till 2030 - Cole of Duty

Physicists Just Quantum Teleported Information Between Particles of Matter – ScienceAlert

By making use of the 'spooky' laws behind quantum entanglement, physicists think have found a way to make information leap between a pair of electrons separated by distance.

Teleporting fundamental states between photonsmassless particles of light is quickly becoming old news, a trick we are still learning to exploit in computing and encrypted communications technology.

But what the latest research has achieved is quantum teleportation between particles of matter electrons something that could help connect quantum computing with the more traditional electronic kind.

"We provide evidence for 'entanglement swapping,' in which we create entanglement between two electrons even though the particles never interact, and 'quantum gate teleportation,' a potentially useful technique for quantum computing using teleportation," says physicist John Nichol from the University of Rochester in New York.

"Our work shows that this can be done even without photons."

Entanglement is physics jargon for what seems like a pretty straightforward concept.

If you buy a pair of shoes from a shop and leave one behind, you'll automatically know which foot it belongs to the moment you get home. The shoes are in a manner of speaking entangled.

If the shopkeeper randomly pulls out its matching partner when you return, you'll think they either remembered your sale, made a lucky guess, or were perhaps a little 'spooky' in their prediction.

The real weirdness arises when we imagine your lonely shoe as being both left and right at the same time, at least until you look at it. At that very moment, the shoe's partner back at the shop also snaps into shape, as if your sneaky peek teleported across that distance.

It's a kind of serendipitous exchange that Einstein felt was a little too spooky for comfort. Nearly a century after physicists raised the possibility, we now know teleportation between entangled particles is how the Universe works on a fundamental level.

While it's not exactly a Star Trek-type teleportation that could beam whole objects across space, the mathematics describing this information jump are mighty useful in carrying out special kinds of calculations in computing.

Typical computer logic is made up of a binary language of bits, labelled either 1s and 0s. Quantum computing is built with qubits that can occupy both states at once providing far greater possibilities that classical technology can't touch.

The problem is the Universe is like a big jumble of shoes, all threatening to turn your delicate game of 'guess which foot' into a nightmare gamble the moment any qubit interacts with its environment.

Manipulating photons to transmit their entangled states is made easier thanks to the fact they can be quickly separated at light speed over huge distances through a vacuum or down an optical fibre.

But separating entangled masses such as pairs of electrons is more of a challenge, given their clunky interactions as they bounce along are almost certain to ruin their mathematically pure quantum state.

It's a challenge well worth the effort, though.

"Individual electrons are promising qubits because they interact very easily with each other, and individual electron qubits in semiconductors are also scalable," saysNichol.

"Reliably creating long-distance interactions between electrons is essential for quantum computing."

To achieve it, the team of physicists and engineers took advantage of some strange fine print in the laws that govern the ways the fundamental particles making up atoms and molecules hold their place.

Any two electrons that share the same quantum spin state can't occupy the same spot in space. But there is a bit of a loophole that says nearby electrons can swap their spins, almost as if your feet could swap shoes if you bring them close enough.

The researchers had previously shownthat this exchange can be manipulated without needing to move the electrons at all, presenting a potential method for teleportation.

This latest advance helps bring the process closer to technological reality, overcoming hurdles that would connect quantum weirdness with existing computing technology.

"We provide evidence for 'entanglement swapping,' in which we create entanglement between two electrons even though the particles never interact, and 'quantum gate teleportation,' a potentially useful technique for quantum computing using teleportation," says Nichol.

"Our work shows that this can be done even without photons."

Of course, we're still some way off replacing photons with electrons for this kind of quantum information transfer. The researchers haven't gone as far as measuring the states of electrons themselves, meaning there could still be all kinds of interference to iron out.

But having strong evidence of the possibility of teleportation between electrons is an encouraging sign of the possibilities open to future engineers.

This research was published in Nature Communications.

Read more from the original source:
Physicists Just Quantum Teleported Information Between Particles of Matter - ScienceAlert

Spain Introduces the World’s First Quantum Phase Battery – News – All About Circuits

By now, were no stranger to the quantum computing hype. When (or rather, if) they are successfully developed and deliver on their promised potential, quantum computers will be able to solve problems and challenges that would otherwise require hundreds or thousands or more years for current classic computer technology to solve.

In what could be a massive step for quantum computing, researchers from the University of the Basque County claim to have developed the worlds first quantum phase battery.

Today, batteries are ubiquitous, with lithium-ion batteries being the most common out of them, although alternatives do exist. These batteries convert chemical energy into a voltage that can provide power to an electronic circuit.

In contrast, quantum technologies feature circuits based on superconducting materials through which a current can flow without voltage, therefore negating the need for classic chemical batteries. In quantum technologies, the current is induced from a phase difference of the wave function of the quantum circuit related to the wave nature of matter.

A quantum device that can provide a persistent phase difference can be used as a quantum phase battery and induce supercurrents in a quantum circuit, powering it.

This is what the researchers set out to achievecreating such a quantum devicebuilding on an idea first conceived in 2015 by Sebastian Bergeret from the Mesoscopic physics group at the Materials Physics Center. Along with Francesco Giazotto and Elia Strambini from the NEST-CNR Institute, Pisa claims to have built the worlds first functional quantum phase battery.

Bergeret and Tokatlys idea, in short, involves a combination of superconducting and magnetic materials with an intrinsic relativistic effect known as spin-orbit coupling. On top of this idea, Giazotto and Strambini identified a suitable material combination that allowed them to fabricate their quantum phase battery.

Their quantum phase battery consists of an n-doped indium arsenide (InAs) nanowire, which forms the core of the cell, also known as the pile, and aluminum superconducting leads act as poles. The battery is charged by applying an external magnetic field, which can then be turned off.

If quantum batteries are ever to be realized, they could bring significant benefits over their chemical cousins. Among other things, quantum batteries could offer vastly better thermodynamic efficiency and ultra-fast charging times, making them perfect for next-gen applications like electric vehicles.

See the article here:
Spain Introduces the World's First Quantum Phase Battery - News - All About Circuits

Quantum Computing Market Size, Analysis, Trends and Segmented Data by Top Companies and Opportunities 2020-2027 – Cole of Duty

New Jersey, United States,- The latest research study on Quantum Computing Market Added by Verified Market Research, offers details on current and future growth trends pertaining to the business besides information on myriad regions across the geographical landscape of the Quantum Computing market. The report also expands on comprehensive details regarding the supply and demand analysis, participation by major industry players and market share growth statistics of the business sphere.

Global Quantum Computing Market was valued at USD 89.35 million in 2016 and is projected to reach USD 948.82 million by 2025, growing at a CAGR of 30.02% from 2017 to 2025.

Download Sample Copy of Quantum Computing Market Report Study 2020-2027 @ https://www.verifiedmarketresearch.com/download-sample/?rid=24845&utm_source=COD&utm_medium=007

The research report on the Quantum Computing market provides a granular assessment of this business vertical and includes information concerning the market tendencies such as revenue estimations, current remuneration, market valuation, and market size over the estimated timeframe.

Major Players Covered in this Report are:

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the global Quantum Computing market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

The scope of the Report:

The report segments the global Quantum Computing market on the basis of application, type, service, technology, and region. Each chapter under this segmentation allows readers to grasp the nitty-gritty of the market. A magnified look at the segment-based analysis is aimed at giving the readers a closer look at the opportunities and threats in the market. It also addresses political scenarios that are expected to impact the market in both small and big ways. The report on the global Quantum Computing market examines changing regulatory scenarios to make accurate projections about potential investments. It also evaluates the risk for new entrants and the intensity of the competitive rivalry.

Ask for Discount on Quantum Computing Market Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24845&utm_source=COD&utm_medium=007

As per the regional scope of the Quantum Computing market:

Highlights of the report:

Key Questions Answered in the report:

Learn More about this report @ https://www.verifiedmarketresearch.com/product/Quantum-Computing-Market/?utm_source=COD&utm_medium=007

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Our Trending Reports

Rugged Display Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Quantum Computing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Sensor Patch Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Data Center Interconnect Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Industrial Lighting Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See the original post here:
Quantum Computing Market Size, Analysis, Trends and Segmented Data by Top Companies and Opportunities 2020-2027 - Cole of Duty

Why You Can’t Call in an Air Strike with an iPhone – War on the Rocks

Christian Brose, The Kill Chain: Defending America in the Future of High-Tech Warfare(Hachette Books, 2020)

Between 1996 and 2011, the U.S. military spent $6 billion to develop and field a new tactical radio. Even in the context of U.S. military spending, $6 billion is a big chunk of change. By comparison, the Air Force spent approximately $3 billion to develop and procure the pathbreaking MQ-1 Predator. The Predator ushered in a new era of drone warfare, whereas the tactical radio project was cancelled before it could produce a single radio.

Harris Communications was one of the companies that hoped to win the contract for this program. The leaders at Harris foresaw the enormous technological and program management challengesthat awaited the winner. Harris didnt win the contract, but that didnt stop the company from taking advantage of the opportunity.Itinvested $200 million of its own research and development dollars to develop a radio system with less ambitious performance goals and that would be unencumbered by unwieldy Pentagon acquisition regulations. Harris succeeded in 2008 with the PRC-117G radio, which could support a modest tactical voice and data network that has since become the workhorse standard for the Army and Marine Corps.

Harris radio has many of the hallmarks in which proponents of greater commercial technology in the U.S. military believe. Namely, nimble commercial firms can be more effective if they are less constrained by the Pentagons cumbersome acquisition bureaucracy. Although Harris is not a Silicon Valley start-up, the success of its radio when compared to the more ambitious radio-that-never-was illustrates the problems of the acquisition system and highlights theattractiveness of letting technologists have more freedom to work.

The discourse about emerging technology in theDepartment of Defensetoday is centered around themilitarypotential of commercially developed information technology. If anything, the role of commercial technology is clearer today than it was in in 1996. Pivotal, a software company, worked with the Air Forces Kessel Run program to transformtanker refueling schedules with easy-to-use software. Artificial intelligence-driven drones have the potential to overwhelm defenses while quantum sensors can detect even stealthy submarines beneath the waves by their minute gravitational signatures on the wavetops. The military potential for these and other commercially developed technologies is substantial.

For many technologists eager to help the U.S. military though,the conversation is often tinged with asense of frustration that the military does not adopt commercial technology more readily than they believe it should. This frustration often focuses on the role of the Department of Defenses acquisition bureaucracy. Congress, for instance, has asked pointed questions to the Army about why it was reluctant to adopt the commercially developedPalantirintelligence analysis software system.And, formerGoogle CEO Eric Schmidtonce proclaimedto the head of U.S. Special Operations Command thatIf I got under your tent for a day, I could solve most of your problems. Tesla and SpaceX CEO Elon Musk confidently stated earlier this year that a manned F-35 would beno matchagainst a semi-autonomous drone in air-to-air combat. There is a strong sense among interested technologists that breakthroughs in the commercial sector will be critical to warfare in the future and that the overly restrictive Pentagon processes and stodgy culture are impediments to that future.

The frustrations of commercial technologists should concern the Department of Defense. The under secretary of defense for research and engineerings modernization priorities include artificial intelligence, biotechnology, and other technologies where the commercial sector is leading development efforts. It is clear that commercial technology companies will be an important part of an expanded defense industrial base, giving weight to technologists concerns. Some firms may find the defense sector to be an economically challenging market; a reputation for frustrating red tape may make it even less attractive. Most concerning, though, is that simple frustrations about Pentagon bureaucracy are an easy conclusion to draw that offers little hope about whether the situation will improve. Such a conclusion obscures deeper exploration into the reasons why commercial technology is not more readily adopted by the military.

Is The System the Only Obstacle?

There is no shortage of criticism of thedefense acquisition bureaucracy, butis that the only reason why troops arent calling in air strikes from iPhones and using artificial intelligence to control drone swarms? Two other reasons might also be considered:first, adapting commercial technology for military purposes is harder than it seems; and second, the military might not be fully convinced that available commercial technologies are what it wants.

Christian Broses new book, The Kill Chain: Defending America in the Future ofHigh-TechWarfare,is aninsightfulanalysisof the bureaucratic obstacles to the adoption of commercial technologies by the U.S. military.His years of experience on Capitol Hill imbue his book with a sense of context thatmoves the conversation past the frustrations that technologists have expressed.He deftly describes the bureaucratic and political power structures and incentives that keep the U.S. military from more readily integrating commercial technology.It is a powerful contribution to the conversation about technology and defense.

Broses critiques are more nuanced than those of many frustrated technologists. However, he still confines hisarguments toissues about the political incentive structure and acquisition bureaucracy. To keep advancing the conversation, we should consider these two possible obstacles alongwith Broses critique of the bureaucracy.

The Bureaucracy Is Imposing Obstacles

In his book, Brose argues that the Pentagons organization, process, and incentives are preventing commercial technology from taking root in the military. He argues that commercial information technologies such as artificial intelligence will define the future of conflict and that the United States is underinvesting both financially and organizationally in those technologies. Meanwhile, Brose argues, Americas adversaries have watched, learned, and stolen a march on new technologies, including artificial intelligence, quantum computing, biotechnology, and space systems.

Brose offers a well-thought-out diagnosis of why this underinvestment exists, even though the United States correctly envisioned the rolethatcommercial information technologies would playas far back as the early 1990s. Americas hubris about its supremacy made it slow to act, he argues, as did a two-decade counter-insurgency and counter-terrorism odysseythatdistracted the United Statesfrom making progress. Brose further argues that the Pentagon is incentivized to value stakeholder consensus over decisiveness, with a budgeting processthat favors incumbent programs over new ones and an acquisition system that favors process compliance over effective outcomes. The result, he believes, is a defense establishment that is unable to change course until it is too late.

Broses observations and arguments about the organizational hurdles to greater commercial technology adoption by the U.S. military forceus to reflecton the values for which the acquisition bureaucracy strives. For instance, his analysis of the acquisition systems prodigious regulatory burdens, which exist to ensure fair competition and save money, forces readers to question the purpose of all the red tape: Is saving pennies worth the trouble when the future of U.S. national security is at stake? Brose believes that, when it comes to confronting emerging great powers with chips on their shoulders and serious military technology ambitions, the United States has done what it did during the Cold War when it pick[ed] winners the people who could succeed where others could not, and the industrialists who could quickly build amazing technology that worked. Other concerns, such as fairness and efficiency, were of secondary importance.

However, there is something to be said for fairness and efficiency. Done right, fair competition yields a diversity of approaches that is more likely to prepare United States to endure the shocks and surprises of clever and adaptive adversaries. Even ballistic missile pioneer Bernard Schriever one of Brosespickedwinners hedged his bets bypursuing multiple approachesthat yielded the Atlas and Titan missiles. Cost-effectiveness is also underrated. Americas national resources are finite. And, theongoing COVID-19 pandemicis only one example that should encourage reflection on budget priorities. Brose correctly diagnoses the ills of the defense acquisition bureaucracy, but its goals are still worthwhile. Brose is right that mindless adherence to acquisition rules without considering the wider context wastes time and effort. One might be better served bycontinuing the hard workofreforming the bureaucracy not sidestepping it.

Defense Technology Is Harder Than It Looks

Another reason why emerging commercial technologies may not be more readily adopted by the Pentagon is that adapting such technology for military use may be harder than it seems. This chance is a distinct possibility. MaaikeVerbruggenargues that military expectations for artificial intelligence should be tempered. Artificial intelligence is not yet capable of performing subjective tasks where judgment is required; for instance, it still struggles to accurately flag disinformation. Recent strides in autonomous vehicles are encouraging, buttechnical challenges remain.And, making themcost effectiveenough for widespread military use will be a significant hurdle. Building a single, robust tactical network to link platforms also remains a much more difficult challenge than it seems.Commercial technologies being adapted for military use might be less technically risky since they are perfected in commercial settings. But, while military performance requirements are often more demanding than commercial ones, the fundamental challenge of being pitted against an actively plotting adversary remains. Brose does not seem to address these issues either.

Technology May Not Even Be the Answer

Finally, we must consider the possibility that the role of commercial technology within the U.S. military may not be desirable in the first place. Brose offers a very specific vision of how artificial intelligence, quantum computing, and networked systems should be wielded by the United States. He paints a detailed picture of sensors that locate adversaries with impunity, a battlefield cluttered with disposable unmanned systems, and networks that will accelerate the tempo of operations to new highs.

This optimistic vision is enthralling, but should it be the goal for which the U.S. military strives? A battlefield network that seamlessly links together sensors and shooterswill accelerate the operational tempo when it works. How will an adaptive adversary seek to disrupt that network and turn its advantage into a liability? How will commanders leverage such connectivity? What role should artificial intelligence play? Will technology enhance initiative and decision-making, further enable micromanagement, or something else?

Brose tangentially examines these issues but only as they concern artificial intelligence and the ethics of armed conflict. He offers a refreshingly nuanced vision of an artificial intelligence that would enhance the abilities of human decision-makers and refrain from making the decisions itself. He forthrightly acknowledges the technological challenges of achieving that ideal. He considers the role of trust and artificial intelligence in military decision-making.

But, Brose never really questions the role of commercial technology and its effect on war in the first place. He admits that the fog of war will never truly lift but still walks readers through a vision of networked warfare where he believes that it does.Some within the defense community urge greater caution about the enthralling vision of networked warfare.LauraSchousboe, B. A. Friedman, and Olivia Garardhave argued that the ultimate role of emerging technologies is still unclear. The interaction of humans both friendly and enemy and systems should be deliberately considered. Commercial technology is likely to play a significant role in future conflict, but the Pentagon should guard against too much optimism.

No Plan Survives First Contact With the Enemy

Brose has made an important contribution to the debate about commercial technology and the military. He sees the throughline between technologies, their military and political uses, and the domestic organizational and political landscapes. He understands that warfare is an inherently chaotic human endeavor that can defy the expectations of optimistic technologists. AsKill Chainpulls it all together in an admirable way, I hope Broseuses his deep knowledge of defense technology issuesto explore the obstacles outlined here as well other ones.

However, technologists and those who share their views should be cautious abouthow the future of armed conflict will play out.The vision of future war that Brose and others imagine is compelling, but the United States wont truly know how this situation will play out until a crisis arrives. The same is true for U.S. adversaries.Emergingcommercialtechnologies will play a role, but the military may wish to consider additional steps tomake their adoption more effectivein the face of such uncertainty.

For instance,the militarymight considerreforming therequirementsprocessto address the issues of desirability and implementation.Reforming requirementsmight help the Pentagonfully leveragethe flexibility offeredby the updated acquisition regulation.This sort of reform canbringclarityto themost useful intersections between emerging technologies and the military, which canalsokeepcost, schedule, and performance expectationsin line with reality.

The Department of Defense can alsopreparefor inevitable surprises.Richard Danzigobservedthatpredictions about the future of war are consistently wrong. It is better to be circumspect about the nature of future conflicts and prepare for predictive failures. The continued attention to rapid acquisition processes is an encouraging sign.Past experienceswith quick responses to unforeseen adversary capabilities also offer lessons to learn.

The radio that Harris Communications built was neither perfect nor the best radio that people could imagine at the time. However, it provided capabilities that were sorely lacking. Its designers accomplished this achievement by combining an understanding of what was technologically possible with a clear grasp of the performance requirements that were most important to users. As the Pentagon and commercial technologists continue to explore the potential of commercial technologies for the military and work towards greater adoption, they may wish to focus not only on lowering bureaucratic barriers but also on managing expectations about what technologies will be most beneficial and how they will be used.

Jonathan Wong is an associate policy researcher at the non-profit, non-partisan RAND Corporation and a non-resident fellow at Marine Corps Universitys Krulak Center for Innovation and Creativity. He can be found on Twitter @jonpwong.

Image: U.S. Air Force (Photo by Staff Sgt. Izabella Workman)

See the rest here:
Why You Can't Call in an Air Strike with an iPhone - War on the Rocks

Why Indian IT Professionals Are Looking To Upskill Themselves In Cloud Computing – Analytics India Magazine

This internet boom over the last two has led to the growth in the demand for bandwidth from data centres. Lack of access to quality data networks and fully amped data centres in India is truly felt among organisations during this novel Coronavirus pandemic. To counter the pressure of work from home scenarios, Indian organisations are investing many times more than traditional IT spending in cloud infrastructure. In addition, cloud companies are expanding fast in the nation.

Even global companies are flocking towards India. For instance, Oracle has come up with its second cloud region in Hyderabad to support customers demand for enterprise cloud services in India. The launch follows the launch of its Mumbai Cloud region in 2019, making India Oracles latest nation with multiple cloud regions available. India has also become the next big hot market for internet giants such as Netflix, Spotify, Facebook and Amazon, fuelling demand for cloud professionals who could manage the digital infrastructure.

Amid this boom, training providers are witnessing a surge in enrolment in their information technology training programmes, including emerging technologies like cloud and data science. The jobs of the future will need expertise specific niche skills, and upskilling is the only way for a long term career growth for technologists. Hence certification programs are getting popularity among the IT professionals. According to analysts, COVID-19 lockdown has catalysed the enthusiasm of techies to getting certified. Indian software programmers are going for cloud certifications amidst COVID-19 lockdown, revealed a survey report from TechGig.

Also Read: 10 Leading Courses & Training Programmes For Cloud Computing In India

Extensive understanding of a new-age technology appeared the most crucial reason for techies to take certifications. Also, freshers and new joiners are more interested in acquiring certifications than working professionals. Cloud technology which is helping communication and remote working amid the present COVID-19 lockdown is also the preferred option for upskilling for the Indian developers, notes TechGig. The preference for cloud came on top of other advanced technologies like artificial intelligence and machine learning.

In todays unique COVID-19 time, technology is the only string which is keeping the world together. From cloud computing, which is supporting work-from-home to artificial intelligence, which is backing banking, retail, and important sectors run operations. Besides, cloud computing is crucial for robotics that is helping the front-line hospital personnel; new-age technologies are assisting the globe to connect in the existing time. The TechGig survey shows the enthusiasm of Indian developers to upskill on these new-age technologies, said Sanjay Goyal, Vice President & Head of Product and Technology at TechGig

Looking for people with cloud skills is a complex endeavour. Organisations these days are finding it very difficult to hire and retain cloud specialists, particularly in roles requiring advanced cloud skills and cloud architecture. Therefore, companies are giving due importance to both finding and creating the skills in-house so they do not face infrastructure challenges. Also, given the introduction of new services from the three major cloud platforms Google Cloud Platform, Amazon Web Services, Microsoft Azure and others, cloud training has to be constant so people can stay on top of the technology. Training providers are witnessing a surge in enrolment in their information technology training programmes, including emerging technologies like cloud and data science.

Cloud technology is one of the leading tech domains for upskilling among the techies and other technologies like artificial intelligence, machine learning, and quantum computing, getting the highest preference in terms of the need for upskilling. According to TechGig IT Certification Survey, one of the most important findings was that 90% of the respondents revealed that they are planning to have an IT certification soon to support and boost their career prospects. Thats why the adoption of certification courses is on the rise.

Also Read: 10 Leading Courses & Training Programmes For Cloud Computing In India

Cloud computing has risen to be the most sought-after skills set in the world for the last few years, and in particular, in 2020, companies are migrating their infrastructure and apps to cloud platforms. As a consequence, cloud jobs are also growing at a swift pace, making it one of the hottest fields in information technology. Now, with the demand for cloud experts, it has fuelled the need for niche skills, and IT professionals know that well.

It is clear that IT professionals will not face any issue with employment opportunities if they are skilled in cloud technologies space, particularly for platforms such as AWS, Google Cloud, Microsoft Azure. Consequently, learners are developing skills so they can grab the jobs as a cloud developer/administrator or system operators for cloud platforms after finishing their training programs. The platforms are utilised by thousands and thousands of businesses worldwide for hosting their products and services.

Home Why Indian IT Professionals Are Looking To Upskill Themselves In Cloud Computing

Cloud training courses will provide professionals with the opportunity to learn the best techniques and practices in cloud computing and acquire live feedback from an expert instructor. Training will help learners to take cloud certification exams from vendors- AWS, Azure or Oracle certifications to get recognised by hiring managers.

The upskilling is spread across advanced classroom training programs run by specialised institutes like Jigsaw Academy and Great Learning, etc, which have also witnessed a surge in demand for enrollment. Apart from training institutes, learners are also flocking to cheaper and/or free courses from cloud vendors or those found on Udemy. In fact, in a recent survey done by Analytics India Magazine, 76.9% of the analytics professionals are spending their time on training through self-learning.

While IT professionals not already working with cloud technologies will gain a solid foundation, those with some cloud experience will gain a more structured and hands-on understanding of cloud technologies, including issues such as migration, deployment, integration, platform choice, and architecture.

According to reports, COVID-19 pandemic has caused the desire to get certified, and professionals understand that certification is a need of the hour amid mass layoffs. DevOps, infrastructure-as-a-service, software-as-a-service, automation, agile and software-defined networks are going to be critical for IT professionals to land these jobs. Some platforms are offering interesting courses for learners to build their cloud tech skills, including many free courses to build cloud tech skills.

Also Read: 10 Leading Courses & Training Programmes For Cloud Computing In India

comments

Vishal Chawla is a senior tech journalist at Analytics India Magazine and writes about AI, data analytics, cybersecurity, blockchain and startup ecosystem. Vishal also hosts AIM's video podcast called Simulated Reality- featuring tech leaders, AI experts, and innovative startups of India. Reach out at vishal.chawla@analyticsindiamag.com

More:
Why Indian IT Professionals Are Looking To Upskill Themselves In Cloud Computing - Analytics India Magazine

Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder – Newswise

Newswise Massachusetts Eye and Ear, a member hospital of Mass General Brigham, is entering into an exclusive licensing agreement with Biogen to develop a potential treatment for inherited retinal degeneration due to mutations in the PRPF31 gene, which are among the most common causes for autosomal dominant retinitis pigmentosa.

Inherited retinal degenerations (IRDs), such as retinitis pigmentosa, are a group of blinding eye diseases caused by mutations in over 270 different genes. Mutations in the PRPF31 gene are the second most common cause of dominant IRD and lead to defects in the function of the retinal pigment epithelial (RPE) cells and photoreceptors of the retina. Previous lab-based research performed by members of the Ocular Genomics Institute at Harvard Ophthalmology, led by Eric A. Pierce, MD, PhD, demonstrated that adeno-associated virus (AAV)-mediated gene augmentation therapy for PRPF31 can restore normal function to PRPF31 mutant RPE cells.

Biogen (Nasdaq: BIIB), a biopharmaceutical company that discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies, will build upon this prior work, and conduct the studies needed for clinical development of PRPF31 gene therapy. This includes the pre-clinical studies needed to support progression to clinical trials of PRPF31 gene therapy. As part of the agreement, Biogen will receive an exclusive license to develop the product worldwide and will be responsible for all U.S. Food and Drug-Administration (FDA) required investigational new drug (IND) enabling studies, clinical development and commercialization.

The treatment of IRDs with highly effective AAV-based gene therapies is core to Biogens ophthalmology strategy, said Chris Henderson, Head of Research, Biogen. This agreement underscores our commitment to that strategy and builds off of our acquisition of Nightstar Therapeutics in 2019 and our active clinical trials of gene therapies for different genetic forms of IRD. We are excited to work with Massachusetts Eye and Ear and look forward to applying our preclinical and clinical experience to their leading PRPF31 program.

We are thrilled to work with Biogen, who will bring to this effort its deep experience with the clinical development process, as we work toward our goal of developing a gene therapy for people with PRPF31-related eye disease, added Dr. Pierce, who is the William F. Chatlos Professor of Ophthalmology at Harvard Medical School. My ultimate hope for patients with inherited retinal disorders due to mutations in PRPF31 is that a gene therapy will preserve and potentially restore some of their vision.

About the Ocular Genomics Institute

The Ocular Genomics Institute at Harvard Ophthalmology aims to translate genomic medicine into precision ophthalmic care for patients with inherited eye disorders. It is home to one of the leading centers for early-phase clinical trials of therapies for inherited retinal degenerations, with seven gene-based and one stem cell trial currently in progress. The group works in conjunction with other departments throughout Harvard Medical School and Mass. Eye and Ear, including the Bioinformatics Center and Grousbeck Gene Therapy Center.

Dr. Pierces lab, established in 2011, is dedicated to research in an effort to improve the understanding of the molecular bases of IRDs so that rational therapies can be developed for these diseases.

In 2018, Mass. Eye and Ear surgeons performed the first post-FDA approval gene therapy for patients with a form of inherited retinal blindness caused by mutations in the gene RPE65 by injecting an AAV-based drug treatment into a patients eye, which restored vision in a 13-year-old boy. This therapy, called Luxturna, is now being used to treat patients with RPE65-associated retinal degeneration around the world.

One of the exciting aspects of our collaboration with Biogen is that mutations in the PRPF31 gene affect approximately 10 to 20 times more people than mutations in the RPE65 gene, said Dr. Pierce. Success with PRPF31 gene therapy could provide visual benefit to more patients, which is our ultimate goal.

Mass. Eye and Ear was one of the first centers to offer life-changing gene therapies to patients with inherited retinal disease, and we are thrilled with this new opportunity to develop a translational retinal therapy that could help even more patients, said Joan W. Miller, MD, Chief of Ophthalmology at Mass. Eye and Ear, Massachusetts General Hospital, and Brigham and Womens Hospital, and Chair of Ophthalmology and the David Glendenning Cogan Professor of Ophthalmology at Harvard Medical School.

According to Chris Coburn, Chief Innovation Officer, Mass General Brigham, the collaboration with Biogen illustrates the importance of academia and industry teaming to solve problems for patients worldwide. We are eager to see this progress reach patients who are challenged by blinding, degenerative eye disease, said Coburn. We look forward to working with Biogen to advance this break-through innovation.

Patients with an inherited retinal disease require genetic testing prior to being considered for any gene therapy treatment.

About Massachusetts Eye and Ear

Massachusetts Eye and Ear, founded in 1824, is an international center for treatment and research and a teaching hospital of Harvard Medical School. A member of Mass General Brigham, Mass. Eye and Ear specializes in ophthalmology (eye care) and otolaryngologyhead and neck surgery (ear, nose and throat care). Mass. Eye and Ear clinicians provide care ranging from the routine to the very complex. Also home to the world's largest community of hearing and vision researchers, Mass. Eye and Ear scientists are driven by a mission to discover the basic biology underlying conditions affecting the eyes, ears, nose, throat, head and neck and to develop new treatments and cures. In the 20192020 Best Hospitals Survey,U.S. News & World Reportranked Mass. Eye and Ear #4 in the nation for eye care and #2 for ear, nose and throat care.For more information about life-changing care and research at Mass. Eye and Ear, visit our blog,Focus, and follow us onInstagram,TwitterandFacebook.

About Harvard Medical School Department of Ophthalmology

The Harvard Medical SchoolDepartment of Ophthalmologyis one of the leading and largest academic departments of ophthalmology in the nation. Composed of nine affiliates (Massachusetts Eye and Ear, which is home to Schepens Eye Research Institute; Massachusetts General Hospital; Brigham and Womens Hospital; Boston Childrens Hospital; Beth Israel Deaconess Medical Center; Joslin Diabetes Center/Beetham Eye Institute; Veterans Affairs Boston Healthcare System; Veterans Affairs Maine Healthcare System; and Cambridge Health Alliance) and several international partners, the department draws upon the resources of a global team to pursue a singular goaleradicate blinding diseases so that all children born today will see throughout their lifetimes. Formally established in 1871, the department is committed to its three-fold mission of providing premier clinical care, conducting transformational research, and providing world-class training for tomorrows leaders in ophthalmology.

Follow this link:
Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder - Newswise

Hitachi and ThinkCyte announce collaboration to develop an AI-driven cell analysis and sorting system – BioSpace

TOKYO, July 1, 2020 /PRNewswire/ --Hitachi, Ltd.(TSE: 6501, "Hitachi") and ThinkCyte, Inc. ("ThinkCyte") today announced that they have entered into a collaboration focused on developing an artificial intelligence (AI)-driven cell analysis and sorting system. Hitachi provides a broad range of solutions such as automated cell culture technologies to pharmaceutical companies in the value chain*1 of the regenerative medicine and cell therapy industry. Through the addition of this cell analysis and sorting system to the value chain, Hitachi continues contributing to cost reductions in the manufacturing of regenerative medicine and cell therapy products.Further, Hitachi and ThinkCyte are promoting collaboration with pharmaceutical companies and research institutes working in the field of regenerative medicine and cell therapy to expedite the development of the system toward commercialization.

The practical applications of regenerative medicine and cell therapy using cells for treatment have been expanding rapidly with the first regulatory approval of CAR-T*2 therapy for leukemia in 2017 in the United States and 2019 in Japan. The global market for regenerative medicine and cell therapy is expected to grow from US$ 5.9 billion (JPY 630 billion) in 2020 to US$ 35.4 billion (JPY 3.8 trillion) in 2025*3. In order to scale up treatment using regenerative medicine and cell therapy products, it is critical to ensure consistent selection and stable supply of high quality cells in large quantities and at a low costs.

Hitachi has been providing large-scale automated induced pluripotent stem (iPS) cell culture equipment, cell processing facilities (CPFs), manufacturing execution systems(MES), and biosafety cabinets among other products to pharmaceutical companies and research institutes, and has developed a value chain to meet a variety of customer needs in the regenerative medicine and cell therapy industry. Hitachi has also been carrying out collaborative research projects with universities, research institutes, and other companies to develop core technologies for pharmaceutical manufacturing instruments and in vitro diagnostic medical devices, prototyping for mass production, and working on manufacturing cost reduction and the development of stable and reliable instruments.

ThinkCyte has been performing research and development focused on high-throughput single cell analysis and sorting technology to precisely analyze and isolate target cells. While such single cell analysis and sorting technologies are vital to life science and medical research, it has been thought impossible to achieve high-throughput cell sorting based on high-content image information of every single cell. ThinkCyte has developed the world's first Ghost Cytometrytechnology to achieve high-throughput and high-content single cell sorting*4and has been conducting collaborative research projects with multiple pharmaceutical companies and research institutes to utilize this technology in life science and medical fields.

Hitachi and ThinkCyte have initiated a joint development of the AI-driven cell analysis and sorting system based on their respective technologies, expertise, and know-how. By combining ThinkCyte's high-throughput and high-content label-free single cell sorting technology and Hitachi's know-how and capability to producing stably operative instruments on a large scale, the two companies will together develop a novel reliable system to enable high-speed label-free cell isolation with high accuracy, which has been difficult to achieve with the existing cell sorting techniques, and to realize stable, low-cost and large-scale production of cells for regenerative medicine and cell therapy.

Hitachi and ThinkCyte will further advance partnerships with pharmaceutical companies and research institutes that have been developing and manufacturing regenerative medicines and cell therapy products in Japan and other countries where demand is expected to be significant, such as North America, in order to make this technology a platform for the production of regenerative medicines and cell therapy products. At the same time, taking advantage of the high-speed digital processing technologies cultivated through the development of information and communication technology by the Hitachi group, Hitachi will integrate this safe and highly reliable instrument in its value chain for regenerative medicine and contribute to the growth of the regenerative medicine and cell therapy industry.

Note:

*1. Cell manufacturing processes, including cultivation, selection, modification, preservation, product quality control, etc.

*2. Chimeric Antigen Receptor T cells that have been genetically engineered to produce an artificial T-cell receptor for use in immunotherapy.

*3. Division of Regenerative Medicine, Japan Agency for Medical Research and Development, The final report for market research on regenerative medicine and gene therapy (2020).

*4. S, Ota et al., Ghost Cytometry, Science, 360, 1246-1251 (2018).

About the AI-driven cell analysis and cell sorting technologyThinkCyte has developed high-throughput image-based cell sorting technology based on the Ghost Cytometry technology by integrating the principles of advanced imaging technology, machine learning, and microfluidics. By applying structured illumination to cell imaging, structural information of a single cell can be converted to one-dimensional waveforms for high-throughput data analysis. Based on the judgment of a machine-learning (AI) model developed using the waveform data, target cells are isolated in a microfluidic device with high throughput and with minimal damage to the cells.

This data analysis approach eliminates time-consuming image reconstruction processes and allows high-throughput image-based single cell sorting, enabling the discrimination of cells that were previously considered difficult to distinguish by the human eye. Conventional cell sorting methods rely on the use of labels such as cell surface markers for cell sorting; in contrast, ThinkCyte's technology can sort cells without such labels by employing this unique approach. In addition to the field of regenerative medicine and cell therapy, this technology can also revolutionize drug discovery and in vitrodiagnostics fields.

About Hitachi, Ltd.Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, is focused on its Social Innovation Business that combines information technology (IT), operational technology (OT) and products. The company's consolidated revenues for fiscal year 2019 (ended March 31, 2020) totaled 8,767.2 billion yen ($80.4 billion), and it employed approximately 301,000 people worldwide. Hitachi drives digital innovation across five sectors - Mobility, Smart Life, Industry, Energy and IT - through Lumada, Hitachi's advanced digital solutions, services, and technologies for turning data into insights to drive digital innovation. Its purpose is to deliver solutions that increase social, environmental and economic value for its customers. For more information on Hitachi, please visit the company's website at https://www.hitachi.com.

About ThinkCyte, Inc.ThinkCyte, headquartered in Tokyo, Japan, is a biotechnology company, which developsinnovative life science research, diagnostics,and treatmentsusingintegrated multidisciplinary technologies, founded in 2016. The company focuses on the research and development of drug discovery, cell therapy, and diagnostic platforms using its proprietary image-based high-throughput cell sorting technology In June 2019, the company was selected for J-Startup by the Ministry of Economy, Trade and Industry of Japan. For more information on ThinkCyte, please visit the company's website at https://thinkcyte.com.

ContactsHitachi, Ltd.Analytical Systems Division, Healthcare Division, Smart Life Business Management Divisionhttps://www8.hitachi.co.jp/inquiry/healthcare/en/general/form.jsp

ThinkCyte, Inc.https://thinkcyte.com/contact

View original content to download multimedia:http://www.prnewswire.com/news-releases/hitachi-and-thinkcyte-announce-collaboration-to-develop-an-ai-driven-cell-analysis-and-sorting-system-301086729.html

SOURCE ThinkCyte, Inc.

Read the rest here:
Hitachi and ThinkCyte announce collaboration to develop an AI-driven cell analysis and sorting system - BioSpace

Image of the Month: Locating molecular players in Batten disease – Baylor College of Medicine News

Mutations in either protein CLN6 or CLN8 result in two forms of Batten disease with remarkably similar clinical features. It turns out, as recently shown by the laboratory of Dr. Marco Sardiello, that both proteins work together to equip lysosomes, the waste-disposal hubs of the cell, of the much needed enzymes that process cellular waste.

Batten disease is a family of 13 rare, genetically distinct conditions. Collectively, they are the most prevalent cause of neurodegenerative disease in children, affecting 1 in 12,500 live births in the U.S. One of the Batten disease genes is CLN6. How mutations in this gene lead to the disease has been a mystery, but a study led by researchers at Baylor College of Medicine and published in the Journal of Clinical Investigation reveals how defective CLN6 can result in Batten disease.

People with Batten disease have problems with their cells ability to clear cellular waste, which then accumulates to toxic levels, said first author Dr. Lakshya Bajaj, who was working on this project while a doctorate student in the Sardiello lab at Baylor. Bajaj is currently a post-doctoral associate at Harvard Medical School.

In cells, lysosomes process cellular waste. They are sacs containing enzymes, a type of proteins that break down waste products into its constituent components that the cell can recycle or discard. In Batten disease caused by mutations in CLN6, the lysosomes do not process waste effectively for unknown reasons. This results in waste accumulation. Batten disease is a type of lysosomal storage disorder. Although all types of cells can be affected by defects in lysosomal waste management, brain cells, neurons, are particularly susceptible.

Waste accumulation in neurons perturbs many cellular processes and eventually results in cell death. This leads to the progressive degeneration of motor, physical and intellectual abilities observed in Batten disease patients, Bajaj said.

The connection of CLN6 with Batten disease was a bit of a mystery. This protein is not found in lysosomes, but in the endoplasmic reticulum, a structure inside cells where proteins, including lysosomal enzymes, are made. The endoplasmic reticulum is separate from the lysosomes. So, how do defects in a protein located outside of the lysosomes interfere with lysosomal function?

The Sardiello lab had previously solved a similar mystery involving CLN8, another protein located in the endoplasmic reticulum and whose mutations also cause a type of Batten disease.

We showed that CNL8 assists on the exit of lysosomal enzymes from the endoplasmic reticulum en route to the lysosomes. When CLN8 is defective, the transport of enzymes from their place of synthesis to the final destination is deficient and the lysosomes end up having fewer enzymes to work with, said Sardiello, associate professor of molecular and human genetics at Baylor and corresponding author of this work.

The clinical manifestations of Batten disease caused by CLN8 mutations and those of Batten disease due to defective CLN6 are remarkably similar. This and other evidence led the researchers to suspect that CLN6 and CLN8 might be working together.

Their investigations revealed that CLN6 and CLN8 do interact with each other forming a molecular complex that collects lysosomal enzymes at the endoplasmic reticulum and mediates their trafficking towards the lysosomes.

We propose that CLN8 and CLN6 together herd the enzymes into a hub, a sort of bus stop. Then, CLN8 escorts the enzymes on the bus en route to the lysosomes, while CLN6 remains at the bus stop. CLN8 returns to the bus stop after delivering the enzymes, and they repeat the process, Bajaj said. When CLN6 is defective, the enzymes are not effectively herded into the bus stop and fewer are transported to the lysosomes.

The researchers are interested in finding whether other factors are involved in transporting enzymes to the lysosomes. For instance, whether there are other bus conductors or herders of lysosomal enzymes involved that, if defective, may also contribute to Batten disease.

Other contributors to this work include Jaiprakash Sharma, Alberto di Ronza, Pengcheng Zhang, Aiden Eblimit, Rituraj Pal, Dany Roman, John R. Collette, Clarissa Booth, Kevin T. Chang, Richard N. Sifers, Sung Y. Jung, Jill M. Weimer, Rui Chen and Randy W. Schekman. The authors are affiliated with one or more of the following institutions: Baylor College of Medicine; Texas Childrens Hospital; University of California, Berkeley; Sanford Research, Sioux Falls, South Dakota; and Sanford School of Medicine at the University of South Dakota.

This work was supported by NIH grants NS079618 and GM127492 and grants from the Gwenyth Gray Foundation, Beyond Batten Disease Foundation and NCL-Stiftung. This project was supported in part by IDDRC grant number 1U54 HD083092 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the Integrated Microscopy Core and the Proteomics Core at Baylor College of Medicine with funding from NIH (DK56338, and CA125123), CPRIT (RP150578, RP170719), the Dan L Duncan Comprehensive Cancer Center and the John S. Dunn Gulf Coast Consortium for Chemical Genomics.

By Ana Mara Rodrguez, Ph.D.

Read this article:
Image of the Month: Locating molecular players in Batten disease - Baylor College of Medicine News

Genetic Modification Therapies Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape,…

The global Genetic Modification Therapies market is expected to exceed more than US$ 3.5 Billion by 2024 at a CAGR of 34% in the given forecast period.

FYI, You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports will now feature detailed analysis that will help you make critical decisions.

Browse Full Report: https://www.marketresearchengine.com/genetic-modification-therapies-market

The global Genetic Modification Therapies market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Genetic Modification Therapies market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Genetic modification therapies, significantly gene therapy and RNA therapy, have existed for many years, with very little clinical success. However, recent enhancements in these therapies, together with higher delivery systems, additional economical and sturdy gene expression constructs, precise polymer editing tools, have brought this industry to the forefront, and its currently poised for explosive growth within the coming back years.

Because of the potentially curative nature of those medicines theres monumental potential in several applications, starting from cancer to neurology to rare diseases. Genetic modification therapies represent consecutive wave of medicines with monumental potential for treating and curing draining and high diseases. As a result of its wide scope, genetic modification therapy can play a vital role within the future world medical economy.

Continuing advances in key technologies like DNA editing, viral design and production, and gene expression, further as a pressing medical want in several serious and enervating disorders, are driving the expansion of the marketplace for genetic modification therapies. Developments in these multidisciplinary fields promise to advance the genetic modification therapies trade and build distinctive market opportunities.

The overall market is anticipated to witness important growth in opportunities for a spread of stakeholders within the returning decade. its necessary to spotlight that many technology suppliers, reaching to develop and / or support the event of gene therapies, with improved effectiveness and safety, have designed and already introduced advanced platforms for the engineering of vectors. Innovation during this domain has additionally semiconductor diode to the invention of novel molecular targets and strong the analysis pipelines of corporations targeted during this house. the potential to focus on numerous therapeutic areas is taken into account to be amongst the foremost outstanding growth drivers of this market.

Market Insights

The global Genetic Modification Therapies market is segregated on the basis of Platform Technology as Gene editing, Gene Therapies, Genetically Modified Cell Therapies, and RNA Therapies. Based on Delivery Technologies the global Genetic Modification Therapies market is segmented in AAV, Adenovirus, Lentivirus, Retrovirus, Other Viral, and Nonviral Based on End-User Industry the global Genetic Modification Therapies market is segmented in Hospitals, Diagnostics and Testing Laboratories, Academic and Research Organizations, and Others.

Based on Disease, the global Genetic Modification Therapies market is segmented in Cardiology, Oncology, Ophthalmology, Hematology, Musculoskeletal, Neurology, Rare Diseases, Other Indications.

Competitive Rivalry

4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore, Jivana Biotechnology, and others are among the major players in the global Genetic Modification Therapies market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.

The Genetic Modification Therapies Market has been segmented as below:

The Genetic Modification Therapies Market is segmented on the lines of Genetic Modification Therapies Market, By Platform Technology, Genetic Modification Therapies Market, By Delivery Technologies, Genetic Modification Therapies Market, By End-User Industry, Genetic Modification Therapies Market, By Disease, Genetic Modification Therapies Market, By Region and Genetic Modification Therapies Market, By Company.

Genetic Modification Therapies Market, By Platform Technology this market is segmented on the basis of Gene editing, Gene Therapies, Genetically Modified Cell Therapies and RNA Therapies. Genetic Modification Therapies Market, By Delivery Technologies this market is segmented on the basis of AAV, Adenovirus, Lentivirus, Retrovirus, Other Viral and Nonviral. Genetic Modification Therapies Market, By End-User Industry this market is segmented on the basis of Hospitals, Diagnostics and Testing Laboratories, Academic and Research Organizations and Others. Genetic Modification Therapies Market, By Disease this market is segmented on the basis of Cardiology, Oncology, Ophthalmology, Hematology, Musculoskeletal, Neurology, Rare Diseases and Other Indications. Genetic Modification Therapies Market, By Region this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World. Genetic Modification Therapies Market, By Company this market is segmented on the basis of 4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore and Jivana Biotechnology.

The report covers:

Report Scope:

The global Genetic Modification Therapies market report scope includes detailed study covering underlying factors influencing the industry trends.

The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.

The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Genetic Modification Therapies market share. Major industry players with significant revenue share include 4D Molecular Therapeutics, Abeona Therapeutics, Beam Therapeutics, Casebia Therapeutics, Editas Medicine, Fate Therapeutics, GE Healthcare, Hitachi Chemical Advanced Therapeutics, Immunocore, Jivana Biotechnology, and others.

Reasons to Buy this Report:

Request Sample Report from here: https://www.marketresearchengine.com/genetic-modification-therapies-market

Table of Contents:

Other Related Market Research Reports:

Guar Gum Market is Forecast to Cross US$ 1.5 Billion by 2024

High Content Screening Market to Grow US$ 1.10 Billion by 2024

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Follow this link:
Genetic Modification Therapies Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape,...

Mitochondrial DNA copy number in cervical exfoliated cells and risk of cervical cancer among HPV-positive women – BMC Blogs Network

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87108.

PubMed PubMed Central Google Scholar

zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2(5):34250.

PubMed Google Scholar

Bloem P, Ogbuanu I. Vaccination to prevent human papillomavirus infections: from promise to practice. PLoS Med. 2017;14(6):e1002325.

PubMed PubMed Central Google Scholar

Arbyn M, Raifu AO, Weiderpass E, Bray F, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer. 2009;45(15):26408.

PubMed Google Scholar

Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr, Kemper AR, Kubik M, et al. Screening for cervical Cancer: US preventive services task force recommendation statement. JAMA. 2018;320(7):67486.

PubMed Google Scholar

Coquillard G, Palao B, Patterson BK. Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. Gynecol Oncol. 2011;120(1):8993.

CAS PubMed Google Scholar

Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matchar DB. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132(10):8109.

CAS PubMed Google Scholar

Gustafsson CM, Falkenberg M, Larsson NG. Maintenance and expression of mammalian mitochondrial DNA. Annu Rev Biochem. 2016;85:13360.

CAS PubMed Google Scholar

Papa S, Skulachev VP. Reactive oxygen species, mitochondria, apoptosis and aging. Mol Cell Biochem. 1997;174(12):30519.

CAS PubMed Google Scholar

Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci U S A. 1997;94(2):5149.

CAS PubMed PubMed Central Google Scholar

Picard M, Wallace DC, Burelle Y. The rise of mitochondria in medicine. Mitochondrion. 2016;30:10516.

CAS PubMed PubMed Central Google Scholar

Lu J, Sharma LK, Bai Y. Implications of mitochondrial DNA mutations and mitochondrial dysfunction in tumorigenesis. Cell Res. 2009;19(7):80215.

CAS PubMed PubMed Central Google Scholar

Kim MM, Clinger JD, Masayesva BG, Ha PK, Zahurak ML, Westra WH, Califano JA. Mitochondrial DNA quantity increases with histopathologic grade in premalignant and malignant head and neck lesions. Clin Cancer Res. 2004;10(24):85125.

CAS PubMed Google Scholar

Lin CS, Chang SC, Wang LS, Chou TY, Hsu WH, Wu YC, Wei YH. The role of mitochondrial DNA alterations in esophageal squamous cell carcinomas. J Thorac Cardiovasc Surg. 2010;139(1):18997 e184.

CAS PubMed Google Scholar

Wang Y, Liu VW, Xue WC, Tsang PC, Cheung AN, Ngan HY. The increase of mitochondrial DNA content in endometrial adenocarcinoma cells: a quantitative study using laser-captured microdissected tissues. Gynecol Oncol. 2005;98(1):10410.

CAS PubMed Google Scholar

Lin CS, Wang LS, Tsai CM, Wei YH. Low copy number and low oxidative damage of mitochondrial DNA are associated with tumor progression in lung cancer tissues after neoadjuvant chemotherapy. Interact Cardiovasc Thorac Surg. 2008;7(6):9548.

PubMed Google Scholar

Lee HC, Li SH, Lin JC, Wu CC, Yeh DC, Wei YH. Somatic mutations in the D-loop and decrease in the copy number of mitochondrial DNA in human hepatocellular carcinoma. Mutat Res. 2004;547(12):718.

CAS PubMed Google Scholar

Wen SL, Zhang F, Feng S. Decreased copy number of mitochondrial DNA: a potential diagnostic criterion for gastric cancer. Oncol Lett. 2013;6(4):1098102.

CAS PubMed PubMed Central Google Scholar

Cui H, Huang P, Wang Z, Zhang Y, Zhang Z, Xu W, Wang X, Han Y, Guo X. Association of decreased mitochondrial DNA content with the progression of colorectal cancer. BMC Cancer. 2013;13:110.

CAS PubMed PubMed Central Google Scholar

Lee HC, Wei YH. Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. Int J Biochem Cell Biol. 2005;37(4):82234.

CAS PubMed Google Scholar

Shokolenko I, Venediktova N, Bochkareva A, Wilson GL, Alexeyev MF. Oxidative stress induces degradation of mitochondrial DNA. Nucleic Acids Res. 2009;37(8):253948.

CAS PubMed PubMed Central Google Scholar

Warburg O. On respiratory impairment in cancer cells. Science. 1956;124(3215):26970.

CAS PubMed Google Scholar

Williams VM, Filippova M, Filippov V, Payne KJ, Duerksen-Hughes P. Human papillomavirus type 16 E6* induces oxidative stress and DNA damage. J Virol. 2014;88(12):675161.

PubMed PubMed Central Google Scholar

Marullo R, Werner E, Zhang H, Chen GZ, Shin DM, Doetsch PW. HPV16 E6 and E7 proteins induce a chronic oxidative stress response via NOX2 that causes genomic instability and increased susceptibility to DNA damage in head and neck cancer cells. Carcinogenesis. 2015;36(11):1397406.

CAS PubMed PubMed Central Google Scholar

Jia M, Han J, Hang D, Jiang J, Wang M, Wei B, Dai J, Zhang K, Guo L, Qi J, et al. HLA-DP is the cervical cancer susceptibility loci among women infected by high-risk human papillomavirus: potential implication for triage of human papillomavirus-positive women. Tumour Biol. 2016;37(6):801925.

CAS PubMed Google Scholar

Hang D, Yin Y, Han J, Jiang J, Ma H, Xie S, Feng X, Zhang K, Hu Z, Shen H, et al. Analysis of human papillomavirus 16 variants and risk for cervical cancer in Chinese population. Virology. 2016;488:15661.

CAS PubMed Google Scholar

Zhu X, Mao Y, Huang T, Yan C, Yu F, Du J, Dai J, Ma H, Jin G. High mitochondrial DNA copy number was associated with an increased gastric cancer risk in a Chinese population. Mol Carcinog. 2017;56(12):2593600.

CAS PubMed Google Scholar

Warowicka A, Kwasniewska A, Gozdzicka-Jozefiak A. Alterations in mtDNA: a qualitative and quantitative study associated with cervical cancer development. Gynecol Oncol. 2013;129(1):1938.

CAS PubMed Google Scholar

Kabekkodu SP, Bhat S, Mascarenhas R, Mallya S, Bhat M, Pandey D, Kushtagi P, Thangaraj K, Gopinath PM, Satyamoorthy K. Mitochondrial DNA variation analysis in cervical cancer. Mitochondrion. 2014;16:7382.

CAS PubMed Google Scholar

Gustinucci D, Giorgi Rossi P, Cesarini E, Broccolini M, Bulletti S, Carlani A, D'Angelo V, DAmico MR, Di Dato E, Galeazzi P, et al. Use of cytology, E6/E7 mRNA, and p16INK4a-Ki-67 to define the Management of Human Papillomavirus (HPV)-positive women in cervical Cancer screening. Am J Clin Pathol. 2016;145(1):3545.

CAS PubMed Google Scholar

Tornesello ML, Buonaguro L, Giorgi-Rossi P, Buonaguro FM. Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. Biomed Res Int. 2013;2013:519619.

PubMed PubMed Central Google Scholar

Feng D, Xu H, Li X, Wei Y, Jiang H, Xu H, Luo A, Zhou F. An association analysis between mitochondrial DNA content, G10398A polymorphism, HPV infection, and the prognosis of cervical cancer in the Chinese Han population. Tumour Biol. 2016;37(4):5599607.

CAS PubMed Google Scholar

Mi J, Tian G, Liu S, Li X, Ni T, Zhang L, Wang B. The relationship between altered mitochondrial DNA copy number and cancer risk: a meta-analysis. Sci Rep. 2015;5:10039.

CAS PubMed PubMed Central Google Scholar

Hu L, Yao X, Shen Y. Altered mitochondrial DNA copy number contributes to human cancer risk: evidence from an updated meta-analysis. Sci Rep. 2016;6:35859.

CAS PubMed PubMed Central Google Scholar

Choi YB, Harhaj EW. Functional implications of mitochondrial reactive oxygen species generated by oncogenic viruses. Front Biol (Beijing). 2014;9(6):42336.

CAS Google Scholar

Mushtaq M, Darekar S, Kashuba E. DNA tumor viruses and cell metabolism. Oxidative Med Cell Longev. 2016;2016:6468342.

Google Scholar

Lai D, Tan CL, Gunaratne J, Quek LS, Nei W, Thierry F, Bellanger S. Localization of HPV-18 E2 at mitochondrial membranes induces ROS release and modulates host cell metabolism. PLoS One. 2013;8(9):e75625.

CAS PubMed PubMed Central Google Scholar

Wei YH, Lee CF, Lee HC, Ma YS, Wang CW, Lu CY, Pang CY. Increases of mitochondrial mass and mitochondrial genome in association with enhanced oxidative stress in human cells harboring 4,977 BP-deleted mitochondrial DNA. Ann N Y Acad Sci. 2001;928:97112.

CAS PubMed Google Scholar

Zhou X, Wang Y, Si J, Zhou R, Gan L, Di C, Xie Y, Zhang H. Laser controlled singlet oxygen generation in mitochondria to promote mitochondrial DNA replication in vitro. Sci Rep. 2015;5:16925.

CAS PubMed PubMed Central Google Scholar

Saleem A, Adhihetty PJ, Hood DA. Role of p53 in mitochondrial biogenesis and apoptosis in skeletal muscle. Physiol Genomics. 2009;37(1):5866.

CAS PubMed Google Scholar

Kulawiec M, Ayyasamy V, Singh KK. p53 regulates mtDNA copy number and mitocheckpoint pathway. J Carcinog. 2009;8:8.

PubMed PubMed Central Google Scholar

Safdar A, Khrapko K, Flynn JM, Saleem A, De Lisio M, Johnston AP, Kratysberg Y, Samjoo IA, Kitaoka Y, Ogborn DI, et al. Exercise-induced mitochondrial p53 repairs mtDNA mutations in mutator mice. Skelet Muscle. 2016;6:7.

PubMed PubMed Central Google Scholar

Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, Hwang PM. p53 regulates mitochondrial respiration. Science. 2006;312(5780):16503.

CAS PubMed Google Scholar

Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993;75(3):495505.

CAS PubMed Google Scholar

Martinez-Zapien D, Ruiz FX, Poirson J, Mitschler A, Ramirez J, Forster A, Cousido-Siah A, Masson M, Vande Pol S, Podjarny A, et al. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53. Nature. 2016;529(7587):5415.

CAS PubMed PubMed Central Google Scholar

Continued here:
Mitochondrial DNA copy number in cervical exfoliated cells and risk of cervical cancer among HPV-positive women - BMC Blogs Network

Fake News and Alternative Facts – KCPW

The Hinckley Institute Radio Hour(Original Air Date: August 25, 2019) This week on the program, we air a forum looking at the vilification of / and distrust in/ the mediathe network of journalists, reporters, editors, producers and newscasters that gather and dispense the news. Referred to by many names: the press, the media, the fourth estate or the great bulwark of freedom; these organizations and individuals play an essential role in democracy and society and enjoy a long history in America, enshrined in the Constitution through the First Amendment in 1791.

Since its inception in the United States, the press has had no official designation or test of certification and is merely a profession guided by a set of ethical standards built on the publics trust. But based on a Galluppoll, trust in the media reached an all-time low in 2016 and has continued to receive unprecedented levels of mistrust from the American populace. Central to this drop in trust is the corresponding rise in accusations of fake news, alternative facts and media bias. But where did these accusations begin? How does one spot a real fake news story? And why is trust in the media important?

Addressing these questions and other concerns surrounding the press is Jennifer Napier-Pearce, editor of the Salt Lake Tribune.

This forum was recorded on April 10, 2019.

Podcast: Play in new window | Download (50.2MB)

Subscribe: Apple Podcasts | Android |

Related

Read the original:

Fake News and Alternative Facts - KCPW

Fake News: What is the Epoch Times and Why Did It Arrive On My Doorstep? – Lost Coast Outpost

Rendering by Freddy Brewster

A worldwide campaign to spread conspiracy theories and misinformation has arrived in Humboldt County in the form of a weird newspaper with the headline: How Chinas Communist Regime Endangered the World. Last Saturday, residents in Eureka and Arcata received unsolicited copies of the Epoch Times, a far-right and pro-Trump newspaper funded by Falun Gong.

Who is Falun Gong, you might ask?

Well it is not a person. Instead it is a religious movement that started in China in the 1990s and has since moved its headquarters to New York. Falun Gong involves a bit of regulated breathing and meditation exercises and was founded by Li Hongzhi. The movement grew in popularity in China and was eventually banned because the Chinese government deemed it an evil cult.

How does a religious movement get banned in China?

Well, China has been known for crushing dissent and members of Falun Gong are just that. According to interviews with NBC News, members of Falun Gong believe the world is headed toward a judgment day, where those labeled communists will be sent to a kind of hell, and those sympathetic to the spiritual community will be spared.

The Epoch Times started in May 2000 and originally focused solely on pushing anti-communinist messaging and generally stayed out of American politics, however that eventually changed.

In October 2009, Li Hongzhi gave a speech at the Epoch Times where he urged the paper to change its course to essentially become more of a newspaper that builds its own revenue and reputation.

As The Epoch Times has made its way from its start-up to where it is today, it has become quite influential, Li Hongzhi said at the meeting. This tells us, then, that even though while running the paper peoples cultivation states may have often been inadequate, the main current has been good and made indelible achievements. Thats excellent. And as for its future prospects, things should only get better and better as you continue, and ordinary people will attach ever greater importance to the paper.

The Epoch Times has exploded in reach over the last few years with 6.1 million followers on Facebook, 67,400 followers on Instagram, 278,000 followers on Twitter and spent around $1 million on countless YouTube ads. The Epoch Times also charter a new course when it came to going to bat for an American politician. Its publishers are all-in for Trump and see him as an ally in the fight against communism in China.

According to analysis by NBC News, over a six-month period in 2019 the Epoch Times spent $1.5 million for nearly 11,000 ads promoting President Trump, more than any organization outside of the Trump campaign itself.

There is nothing nefarious about showing blatant support for a political figure; mainstream news outlets do it all the time on both sides of the political aisle. However, most of them do not peddle baseless conspiracy theories, align themselves with QAnonand publish misinformation about COVID-19. (Although, there is some debate about this too.)

So why did the Epoch Times end up on peoples doorsteps in Humboldt County?

It was actually part of an international campaign to deliver the paper. Residents in the United Kingdom also found the paper on their doorstep, along with residents in the Bay Area, in Colorado and even Canada.

One LoCO reader in Eureka was so upset about the incident she emailed us the following:

So if you were one of the (un)lucky ones to find a copy of the Epoch Times in your mailbox or on your front step consider reusing it. You can make papier-mch, or airplanes, or use it for a fire starter for your wood burning stove. Or just line the bottom of a bird cage with it because, after all, the paper is total shit.

More:

Fake News: What is the Epoch Times and Why Did It Arrive On My Doorstep? - Lost Coast Outpost